SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Janssen Therapeutics Release: FDA Approves Label Update for PREZISTA(R) to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment